Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study

por Lawitz, Eric, Poordad, Fred, Gutierrez, Julio A., Beumont, Maria, Beets, Greet, Vandevoorde, Ann, Remoortere, Pieter Van, Luo, Donghan, Vijgen, Leen, Eygen, Veerle Van, Gamil, Mohamed
Publicado 2020